Comis concedes that another roadblock to higher trial enrollment is public perceptions of safety issues with being in a trial. News accounts of safety problems with gene therapy trials have dominated headlines in recent months.
As part of his announcement Wednesday, Clinton emphasized that private-sector health plans also should cover the costs of those in trials. The new Medicare policy likely will heighten the pressure on these plans, but many already have taken some steps. Most New Jersey plans, for example, announced last year that they would cover routine clinical trial costs. UnitedHealth Group and Aetna/U.S. Healthcare also have stepped up their national coverage.
The health insurance industry, however, opposes any mandate that plans must cover the costs. Health plans have been concerned that those in clinical trials may have higher expenses for standard doctor visits and lab tests than those patients not in trials. Plans also are worried that not all trials are well structured or legitimate.
That concern extends to the Medicare announcement. Karen Ignagni, president of the American Association of Health Plans, says, "We hope that the Administration will ... ensure that only the highest quality of clinical trials will be encouraged."
Clinical trials provisions are featured in the "Patients' Bill of Rights" on which Congress is struggling to reach final agreement. Senate legislation would require plans to cover costs for cancer trials, but the broader House bill would require coverage for patients in all clinical studies.